The global HLA typing market is projected to reach USD 1.7 billion by 2025 from USD 1.2 billion in 2019, at a CAGR of 5.9%. Growth in the HLA typing market is mainly driven by factors such as the increasing number of HLA typing procedures conducted, technological advancements in the field of HLA typing, and increasing funding for research. However, the high costs of HLA typing products and limited reimbursements for target procedures are expected to restrain market growth in the coming years. Along with this, the significant supply-demand gap between the number of organ donors and organs required annually is expected to challenge market growth to a certain extent.
The major players operating in the HLA typing market are Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Immucor, Inc. (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK), among others.
To know about the assumptions considered for the study download the pdf brochure
The analysis of market developments between 2016 and 2019 revealed that several growth strategies such as product launches, agreements, partnerships, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the HLA typing market.
Thermo Fisher Scientific (US) dominated the global HLA typing market in 2019. It is one of the leading manufacturers of life science research and medical diagnostic products. The company focuses on launching technologically advanced products to maintain its leadership in the HLA typing industry. Furthermore, the company focuses on strengthening its revenue growth and brand positioning by adopting strategies such as acquisitions and expansions. Pertaining to this, Thermo Fisher Scientific acquired several companies to further enhance its presence in the market. These acquisitions enabled the company to expand and strengthen its product portfolio and develop innovative diagnostic technologies. Owing to its wide portfolio of molecular diagnostics products and strong geographic presence, the company is bound to witness growth in the coming years.
QIAGEN (Netherlands) holds the second-leading position in the HLA typing industry, due to its vast product portfolio in molecular diagnostics and analytics. Over the years, the company has focused on multiple growth strategies, such as agreements, collaborations, and product launches. Along with this, the company has maintained continuous leadership in the HLA typing industry with its huge consumer base. It has also strengthened its R&D capabilities for the development of innovative HLA typing products to expand its consumer base and offer novel products.
Illumina (US) dominates the HLA typing market with its technologically advanced and innovative product portfolio. The company’s portfolio includes a wide range of highly interconnected products, including sequencing, genotyping, gene expression, and molecular diagnostic products. The company also offers HLA typing reagents & consumables, instruments, and software & services. Over the past three years, Illumina launched several sequencing products to sustain its leadership in the market and invested significantly in R&D. The company has also entered into agreements with many top genomics players.
HLA Typing Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent), Application (Cancer research, infectious & Non infectious diseases, Transfusion therapy), End User (Hospital, Academia and Research) - Global Forecast to 2025
Mr. Sanjay Gupta
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE